Counterfeit Semaglutide Causes Hypoglycemic Coma: Dangerous Fake Drug Warning

Case report of hypoglycemic coma caused by a falsified semaglutide product highlights the dangerous consequences of counterfeit GLP-1 drug products entering the market.

Antonacci, Giulia et al.·European journal of hospital pharmacy : science and practice·2025·Preliminary Evidencecase series
RPEP-09953Case seriesPreliminary Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
case series
Evidence
Preliminary Evidence
Sample
N=1
Participants
31-year-old woman who used a counterfeit semaglutide product for weight loss

What This Study Found

Case report of hypoglycemic coma caused by a falsified semaglutide product highlights the dangerous consequences of counterfeit GLP-1 drug products entering the market.

Key Numbers

31-year-old woman admitted with hypoglycemic coma after using a falsified semaglutide product.

How They Did This

In publication.

Why This Research Matters

Relevant to peptide therapeutics.

The Bigger Picture

Advances peptide evidence.

What This Study Doesn't Tell Us

In publication.

Questions This Raises

  • ?Long-term implications?
  • ?Evidence comparison?
  • ?Next steps?

Trust & Context

Key Stat:
Key finding Case report of hypoglycemic coma caused by a falsified semaglutide product highlights the dangerous
Evidence Grade:
Based on design.
Study Age:
Published in 2025.
Original Title:
Hypoglycaemic coma induced by a falsified semaglutide product: a case report.
Published In:
European journal of hospital pharmacy : science and practice (2025)
Database ID:
RPEP-09953

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

What does this mean?

Case report of hypoglycemic coma caused by a falsified semaglutide product highlights the dangerous consequences of counterfeit GLP-1 drug products entering the market.

How reliable?

Consult publication.

Read More on RethinkPeptides

Cite This Study

RPEP-09953·https://rethinkpeptides.com/research/RPEP-09953

APA

Antonacci, Giulia; Bortignon, Erika; Bolognesi, Massimo; Piano, Salvatore Silvio; Cadore, Alessandro; Camuffo, Laura; Venturini, Francesca; Faoro, Sonia; Favretto, Donata; Romano, Antonietta; Mengato, Daniele. (2025). Hypoglycaemic coma induced by a falsified semaglutide product: a case report.. European journal of hospital pharmacy : science and practice. https://doi.org/10.1136/ejhpharm-2025-004656

MLA

Antonacci, Giulia, et al. "Hypoglycaemic coma induced by a falsified semaglutide product: a case report.." European journal of hospital pharmacy : science and practice, 2025. https://doi.org/10.1136/ejhpharm-2025-004656

RethinkPeptides

RethinkPeptides Research Database. "Hypoglycaemic coma induced by a falsified semaglutide produc..." RPEP-09953. Retrieved from https://rethinkpeptides.com/research/antonacci-2025-hypoglycaemic-coma-induced-by

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.